A Phase 3 interventional study of Fluarix® and Boostrix® in Acellular Pertussis, Diphtheria and Tetanus, sponsored by GlaxoSmithKline. Completed at 12 sites in United States. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-10.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing boostrix in Diphtheria — 3 open to participants now, 3 under way, none of them phase 3. Boostrix · Diphtheria.
Among the 21 studies testing boostrix in Diphtheria, this one is the 2nd largest by enrollment, is one of 4 that started in 2006, is one of 10 in phase 3, and was the 4th registered.
267 studies on the registry are indexed under Diphtheria; 17 are open to participants now.
Browse Diphtheria studies →3 of the 21 studies testing boostrix in Diphtheria are open now, in 2 countries. Recruiting first, the newest first:
Changchun BCHT Biotechnology Co. · Sites in China
Ages 10+ · Healthy volunteers
Canadian Immunization Research Network · Sites in Canada
Ages 18–49 · Women only
Changchun BCHT Biotechnology Co.
Ages 10+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 11 Diphtheria studies recruiting now, 2 (18%) set no upper age limit and 9 (82%) stop at 75 or younger; 7 take children under 18; 10 take healthy volunteers.
This study: 19 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 4 started in 2006.
This study's enrollment of 1,726 is above the median of 448 across 241 interventional studies indexed under Diphtheria.
Median enrollment 460 across the 21 interventional studies. Of the 18 that completed or were terminated, 12 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 21 have an industry lead sponsor. The 4 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
101 studies in Diphtheria by GlaxoSmithKline: none open now, 1 under way, 1 of them phase 3. Of 99 finished, 59 (60%) have results posted.
Among the 101 studies in Diphtheria by GlaxoSmithKline, this one is the 6th largest by enrollment of the 92 interventional ones that give a count, is one of 12 that started in 2006, is one of 55 in phase 3, and was the 32nd registered.
GlaxoSmithKline’s Diphtheria studies by the year they started, since 1997.
1 of the studies testing boostrix in Diphtheria that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07097012Canadian Immunization Research NetworkConcurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies testing boostrix in Diphtheria, from their registry updates:
Among GlaxoSmithKline’s 101 in Diphtheria:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The current study will provide information for the use of Boostrix concomitantly with influenza vaccine in adults aged 19-64 years. This study will also provide safety and immunogenicity data in a cohort of adults aged greater than or equal to 65 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy male or female adults, aged between 19 to 64 years of age inclusive and 65 years or older, who received Boostrix® vaccine co-administered with Fluarix® vaccine at Day 0, injected intramuscularly in the left and right upper deltoid regions, respectively.
Biological: Fluarix® · Biological: Boostrix®
Healthy male or female adults, aged between 19 to 64 years of age inclusive and 65 years or older, who received Fluarix® vaccine at Day 0 and Boostrix® vaccine at Month 1, both injected intramuscularly in the upper left deltoid region.
Biological: Fluarix® · Biological: Boostrix®
Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Toxoid Antigens
A seroprotected subject was defined as a vaccinated subject with anti-D and anti-T antibody concentrations equal to or above (≥) 0.1 International Units per milliliter (IU/mL), respectively.
Time frame: At Month 1 post-Boostrix® vaccination
Number of Subjects With Anti-T Antibody Concentrations ≥ the Assay Cut-off Value
The assay cut-off value was ≥ 1.0 IU/mL, as assessed by enzyme-linked immunosorbent assay (ELISA).
Time frame: At Month 1 post-Boostrix® vaccination
Antibody Concentrations Against Pertussis Toxoid (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN) Antigens
Anti-PT, anti-FHA and anti-PRN antibody concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U/mL).
Time frame: At Month 1 post-Boostrix® vaccination
Number of Subjects With Serum Haemagglutinin Inhibition (HI) Titers Against 3 Strains of Influenza
The antibody titer cut-off value for the 3 influenza strains assessed (H1N1, H3N2 and B) was ≥ 1:40.
Time frame: At Month 1 post-Fluarix® vaccination
Number of Seroconverted Subjects Against Influenza Antigens H1N1, H3N2, and B
Seroconversion for HI antibodies is defined as: For initially seronegative subjects: post-vaccination antibody titer ≥ 1:40 at Month 1 post-Boostrix® vaccination; For initially seropositive subjects: antibody titer at Month 1≥ 4 fold the pre-vaccination antibody titer.
Time frame: At Month 1 post-Fluarix® vaccination
Number of Seropositive Subjects With Anti-D Antibody Concentrations Above the Cut-off Value
A seropositive subject was a subject whose antibody concentration was greater than or equal (≥) to the cut-off value of 1.0 IU/mL.
Time frame: At Month 1 post-Boostrix® vaccination
Antibody Concentrations for Diphteria Toxoid (D) and Tetanus Toxoid (T)
Anti-D and anti-T antibody concentrations are presented as geometric mean concentrations (GMCs), expressed in International Units per milliliter (IU/mL).
Time frame: At Day 0 and Month 1 post-Boostrix® vaccination
Antibody Concentrations for Pertussis Toxoid (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN)
Anti-PT, anti-FHA and anti-PRN antibody concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U/mL).
Time frame: At Day 0 and Month 1 post-Boostrix® vaccination
Number of Subjects With Booster Response Against Diphteria Toxoid (D) and Tetanus Toxoid (T) Antigens
Booster responses for anti-D and anti-T antibodies are defined as: For initially seronegative subjects \[pre-vaccination concentration below (\<) cut-off 0.1 IU/mL\]: antibody concentrations at least four times the assay cut-off (post-vaccination concentration ≥ 0.4 IU/mL), one month after vaccination with Boostrix®; For initially seropositive subjects (pre-vaccination concentration ≥ 0.1 IU/mL): an increase in antibody concentrations of at least four times the pre-vaccination concentration, one month after vaccination with Boostrix®.
Time frame: At Month 1 post-Boostrix® vaccination
Number of Subjects With Booster Response Against Pertussis Toxoid (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN) Antigens
Booster responses for anti-PT, anti-FHA and anti-PRN are defined as: For initially seronegative subjects (pre-vaccination concentration \< cut-off of 5 EL.U/mL): antibody concentrations at least four times the cut-off (post-vaccination concentration ≥ 20 EL.U/mL), one month after vaccination with Boostrix®; For initially seropositive subjects with pre-vaccination concentration ≥ 5 EL.U/mL and \< 20 EL.U/mL: an increase in antibody concentrations of at least four times the pre-vaccination concentration one month after vaccination with Boostrix®; For initially seropositive subjects with pre-vaccination concentration ≥ 20 EL.U/mL: an increase in antibody concentrations of at least two times the pre-vaccination concentration one month after vaccination with Boostrix®.
Time frame: At Month 1 post-Boostrix® vaccination
Anti-H1N1, Anti-H3N2 and Anti-B Antibody Titers
Anti-H1N1, anti-H3N2 and anti-B antibody titers are presented as geometric mean titers (GMTs).
Time frame: At Month 1 post-Fluarix® vaccination
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site. Subjects from Boostrix+Fluarix Groups (19-64 YOA and ≥ 65 YOA) received only one vaccination dose (Boostrix® vaccine co-administered with Fluarix® vaccine), at Day 0.
Time frame: During the 15-day (Day 0-14) period following each dose and across doses, up to 2 months
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Assessed solicited general symptoms were fatigue, fever \[defined as oral temperature equal to or above (≥) 37.5 degrees Celsius (°C)\], gastrointestinal (nausea, vomiting, diarrhoea and/or abdominal pain), headache, joint pain, muscle aches and shivering. Any = occurrence of the symptom regardless of intensity grade or relationship to the study vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. Subjects from Boostrix+Fluarix Groups (19-64 YOA and ≥ 65 YOA) received only one vaccination dose (Boostrix® vaccine co-administered with Fluarix® vaccine), at Day 0.
Time frame: During the 15-day (Day 0-14) period following each dose and across doses, up to 2 months
Number of Subjects With Any Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Time frame: During the 31-day period (Day 0-30) following each vaccination, up to 2 months
Number of Subjects With Serious Adverse Events (SAEs)
SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: Throughout the whole study period (from Day 0 to Month 2)
| Milestone | Boostrix+Fluarix Group | Fluarix Boostrix Group |
|---|---|---|
| Started | 860 | 858 |
| ≥ 65 years of age (yoa) cohort | 112 | 109 |
| 19-64 years of age (yoa) cohort | 748 | 749 |
| Completed | 839 | 785 |
| Not completed | 21 | 73 |
| Withdrew: Serious adverse event | 1 | 2 |
| Withdrew: Protocol violation | 0 | 4 |
| Withdrew: Withdrawal by subject | 0 | 8 |
| Withdrew: Migrated/moved from study area | 0 | 1 |
| Withdrew: Lost to follow-up | 20 | 58 |
A seroprotected subject was defined as a vaccinated subject with anti-D and anti-T antibody concentrations equal to or above (≥) 0.1 International Units per milliliter (IU/mL), respectively.
| Participants | Boostrix+Fluarix 19-64 YOA Group | Fluarix Boostrix 19-64 YOA Group | Boostrix+Fluarix ≥ 65 YOA Group | Fluarix Boostrix ≥ 65 YOA Group |
|---|---|---|---|---|
| Anti-D | 677 | 614 | 93 | 79 |
| Anti-T | 700 | 653 | 105 | 95 |
The assay cut-off value was ≥ 1.0 IU/mL, as assessed by enzyme-linked immunosorbent assay (ELISA).
| Participants | Boostrix+Fluarix 19-64 YOA Group | Fluarix Boostrix 19-64 YOA Group | Boostrix+Fluarix ≥ 65 YOA Group | Fluarix Boostrix ≥ 65 YOA Group |
|---|---|---|---|---|
| Number of Subjects With Anti-T Antibody Concentrations ≥ the Assay Cut-off Value | 687 | 621 | 94 | 84 |
Anti-PT, anti-FHA and anti-PRN antibody concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U/mL).
| EL.U/mL | Boostrix+Fluarix 19-64 YOA Group | Fluarix Boostrix 19-64 YOA Group | Boostrix+Fluarix ≥ 65 YOA Group | Fluarix Boostrix ≥ 65 YOA Group |
|---|---|---|---|---|
| Anti-PT | 57.5 (53.1 to 62.3) | 76.9 (71.1 to 83.2) | 51.2 (40.8 to 64.2) | 59.3 (47.0 to 74.8) |
| Anti-FHA | 467.6 (434.9 to 502.8) | 663.3 (613.3 to 717.4) | 502.5 (409.5 to 616.7) | 669.6 (539.1 to 831.8) |
| Anti-PRN | 234.9 (208.7 to 264.3) | 343.6 (302.5 to 390.1) | 87.9 (60.1 to 128.5) | 97.0 (68.1 to 138.4) |
The antibody titer cut-off value for the 3 influenza strains assessed (H1N1, H3N2 and B) was ≥ 1:40.
| Participants | Boostrix+Fluarix 19-64 YOA Group | Fluarix Boostrix 19-64 YOA Group | Boostrix+Fluarix ≥ 65 YOA Group | Fluarix Boostrix ≥ 65 YOA Group |
|---|---|---|---|---|
| Anti-H1N1 | 669 | 643 | 92 | 88 |
| Anti-H3N2 | 694 | 663 | 104 | 95 |
| Anti-B | 685 | 654 | 107 | 101 |
Seroconversion for HI antibodies is defined as: For initially seronegative subjects: post-vaccination antibody titer ≥ 1:40 at Month 1 post-Boostrix® vaccination; For initially seropositive subjects: antibody titer at Month 1≥ 4 fold the pre-vaccination antibody titer.
| Participants | Boostrix+Fluarix 19-64 YOA Group | Fluarix Boostrix 19-64 YOA Group | Boostrix+Fluarix ≥ 65 YOA Group | Fluarix Boostrix ≥ 65 YOA Group |
|---|---|---|---|---|
| Anti-H1N1 | 414 | 377 | 37 | 32 |
| Anti-H3N2 | 560 | 494 | 72 | 64 |
| Anti-B | 463 | 425 | 41 | 43 |
A seropositive subject was a subject whose antibody concentration was greater than or equal (≥) to the cut-off value of 1.0 IU/mL.
| Participants | Boostrix+Fluarix 19-64 YOA Group | Fluarix Boostrix 19-64 YOA Group | Boostrix+Fluarix ≥ 65 YOA Group | Fluarix Boostrix ≥ 65 YOA Group |
|---|---|---|---|---|
| Number of Seropositive Subjects With Anti-D Antibody Concentrations Above the Cut-off Value | 579 | 528 | 55 | 49 |
Anti-D and anti-T antibody concentrations are presented as geometric mean concentrations (GMCs), expressed in International Units per milliliter (IU/mL).
| IU/mL | Boostrix+Fluarix 19-64 YOA Group | Fluarix Boostrix 19-64 YOA Group | Boostrix+Fluarix ≥ 65 YOA Group | Fluarix Boostrix ≥ 65 YOA Group |
|---|---|---|---|---|
| Anti-D, Day 0 | 0.4 (0.4 to 0.4) | 0.4 (0.3 to 0.4) | 0.2 (0.1 to 0.2) | 0.2 (0.2 to 0.3) |
| Anti-D, Month 1 | 3.1 (2.8 to 3.5) | 3.4 (3.0 to 3.8) | 1.0 (0.7 to 1.4) | 1.0 (0.6 to 1.4) |
| Anti-T, Day 0 | 1.5 (1.4 to 1.7) | 1.5 (1.3 to 1.6) | 0.5 (0.4 to 0.7) | 0.6 (0.4 to 0.8) |
| Anti-T, Month 1 | 6.5 (6.0 to 7.0) | 7.6 (7.0 to 8.2) | 3.4 (2.7 to 4.3) | 3.6 (2.6 to 5.0) |
Anti-PT, anti-FHA and anti-PRN antibody concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U/mL).
| EL.U/mL | Boostrix+Fluarix 19-64 YOA Group | Fluarix Boostrix 19-64 YOA Group | Boostrix+Fluarix ≥ 65 YOA Group | Fluarix Boostrix ≥ 65 YOA Group |
|---|---|---|---|---|
| Anti-PT, Day 0 | 6.4 (5.9 to 6.9) | 6.5 (6.0 to 7.1) | 8.0 (6.4 to 10.0) | 8.0 (6.4 to 9.9) |
| Anti-PT, Month 1 | 57.5 (53.1 to 62.3) | 76.9 (71.1 to 83.2) | 51.2 (40.8 to 64.2) | 59.3 (47.0 to 74.8) |
| Anti-FHA, Day 0 | 36.6 (33.7 to 39.9) | 36.2 (33.2 to 39.5) | 54.5 (43.2 to 68.7) | 59.0 (46.5 to 75.0) |
| Anti-FHA, Month 1 | 467.6 (434.9 to 502.8) | 663.3 (613.3 to 717.4) | 502.5 (409.5 to 616.7) | 669.6 (539.1 to 831.8) |
| Anti-PRN, Day 0 | 12.6 (11.4 to 13.9) | 12.9 (11.7 to 14.3) | 7.5 (5.9 to 9.4) | 6.4 (5.0 to 8.2) |
| Anti-PRN, Month 1 | 234.9 (208.7 to 264.3) | 343.6 (302.5 to 390.1) | 87.9 (60.1 to 128.5) | 97.0 (68.1 to 138.4) |
Booster responses for anti-D and anti-T antibodies are defined as: For initially seronegative subjects \[pre-vaccination concentration below (\<) cut-off 0.1 IU/mL\]: antibody concentrations at least four times the assay cut-off (post-vaccination concentration ≥ 0.4 IU/mL), one month after vaccination with Boostrix®; For initially seropositive subjects (pre-vaccination concentration ≥ 0.1 IU/mL): an increase in antibody concentrations of at least four times the pre-vaccination concentration, one month after vaccination with Boostrix®.
| Participants | Boostrix+Fluarix 19-64 YOA Group | Fluarix Boostrix 19-64 YOA Group | Boostrix+Fluarix ≥ 65 YOA Group | Fluarix Boostrix ≥ 65 YOA Group |
|---|---|---|---|---|
| Anti-D | 487 | 459 | 61 | 48 |
| Anti-T | 293 | 320 | 62 | 63 |
Booster responses for anti-PT, anti-FHA and anti-PRN are defined as: For initially seronegative subjects (pre-vaccination concentration \< cut-off of 5 EL.U/mL): antibody concentrations at least four times the cut-off (post-vaccination concentration ≥ 20 EL.U/mL), one month after vaccination with Boostrix®; For initially seropositive subjects with pre-vaccination concentration ≥ 5 EL.U/mL and \< 20 EL.U/mL: an increase in antibody concentrations of at least four times the pre-vaccination concentration one month after vaccination with Boostrix®; For initially seropositive subjects with pre-vaccination concentration ≥ 20 EL.U/mL: an increase in antibody concentrations of at least two times the pre-vaccination concentration one month after vaccination with Boostrix®.
| Participants | Boostrix+Fluarix 19-64 YOA Group | Fluarix Boostrix 19-64 YOA Group | Boostrix+Fluarix ≥ 65 YOA Group | Fluarix Boostrix ≥ 65 YOA Group |
|---|---|---|---|---|
| Anti-PT | 514 | 530 | 71 | 68 |
| Anti-FHA | 651 | 621 | 94 | 91 |
| Anti-PRN | 630 | 589 | 79 | 77 |
Anti-H1N1, anti-H3N2 and anti-B antibody titers are presented as geometric mean titers (GMTs).
| Titers | Boostrix+Fluarix 19-64 YOA Group | Fluarix Boostrix 19-64 YOA Group | Boostrix+Fluarix ≥ 65 YOA Group | Fluarix Boostrix ≥ 65 YOA Group |
|---|---|---|---|---|
| Anti-H1N1 | 189.1 (171.7 to 208.3) | 181.6 (165.5 to 199.3) | 79.9 (65.0 to 98.3) | 89.3 (72.8 to 109.5) |
| Anti-H3N2 | 368.7 (337.9 to 402.3) | 337.3 (309.2 to 367.9) | 333.6 (267.8 to 415.5) | 276.8 (212.4 to 360.8) |
| Anti-B | 210.1 (194.4 to 227.0) | 222.8 (205.9 to 241.1) | 221.2 (184.3 to 265.4) | 214.3 (175.4 to 261.8) |
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site. Subjects from Boostrix+Fluarix Groups (19-64 YOA and ≥ 65 YOA) received only one vaccination dose (Boostrix® vaccine co-administered with Fluarix® vaccine), at Day 0.
| Participants | Boostrix+Fluarix 19-64 YOA Group | Fluarix Boostrix 19-64 YOA Group | Boostrix+Fluarix ≥ 65 YOA Group | Fluarix Boostrix ≥ 65 YOA Group |
|---|---|---|---|---|
| Any Pain, Dose 1 | 467 | 315 | 41 | 25 |
| Grade 3 Pain, Dose 1 | 28 | 7 | 0 | 1 |
| Any Redness, Dose 1 | 180 | 148 | 23 | 15 |
| Grade 3 Redness, Dose 1 | 4 | 5 | 3 | 2 |
| Any Swelling, Dose 1 | 179 | 93 | 18 | 11 |
| Grade 3 Swelling, Dose 1 | 12 | 7 | 3 | 1 |
| Any Pain, Dose 2 | 0 | 327 | 0 | 30 |
| Grade 3 Pain, Dose 2 | 0 | 9 | 0 | 3 |
| Any Redness, Dose 2 | 0 | 124 | 0 | 16 |
| Grade 3 Redness, Dose 2 | 0 | 3 | 0 | 2 |
| Any Swelling, Dose 2 | 0 | 106 | 0 | 9 |
| Grade 3 Swelling, Dose 2 | 0 | 6 | 0 | 0 |
| Any Pain, Across doses | 467 | 429 | 41 | 44 |
| Grade 3 Pain, Across doses | 28 | 15 | 0 | 4 |
| Any Redness, Across doses | 180 | 207 | 23 | 20 |
| Grade 3 Redness, Across doses | 4 | 8 | 3 | 4 |
| Any Swelling, Across doses | 179 | 160 | 18 | 17 |
| Grade 3 Swelling, Across doses | 12 | 12 | 3 | 1 |
Assessed solicited general symptoms were fatigue, fever \[defined as oral temperature equal to or above (≥) 37.5 degrees Celsius (°C)\], gastrointestinal (nausea, vomiting, diarrhoea and/or abdominal pain), headache, joint pain, muscle aches and shivering. Any = occurrence of the symptom regardless of intensity grade or relationship to the study vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. Subjects from Boostrix+Fluarix Groups (19-64 YOA and ≥ 65 YOA) received only one vaccination dose (Boostrix® vaccine co-administered with Fluarix® vaccine), at Day 0.
| Participants | Boostrix+Fluarix 19-64 YOA Group | Fluarix Boostrix 19-64 YOA Group | Boostrix+Fluarix ≥ 65 YOA Group | Fluarix Boostrix ≥ 65 YOA Group |
|---|---|---|---|---|
| Any Fatigue, Dose 1 | 220 | 165 | 20 | 18 |
| Grade 3 Fatigue, Dose 1 | 22 | 15 | 0 | 1 |
| Related Fatigue, Dose 1 | 144 | 103 | 15 | 12 |
| Any Fever, Dose 1 | 54 | 52 | 4 | 3 |
| Grade 3 Fever, Dose 1 | 1 | 0 | 0 | 0 |
| Related Fever, Dose 1 | 28 | 28 | 3 | 2 |
| Any Gastrointestinal, Dose 1 | 121 | 101 | 18 | 12 |
| Grade 3 Gastrointestinal, Dose 1 | 16 | 11 | 2 | 1 |
| Related Gastrointestinal, Dose 1 | 68 | 55 | 12 | 6 |
| Any Headache, Dose 1 | 225 | 197 | 17 | 17 |
| Grade 3 Headache, Dose 1 | 24 | 25 | 2 | 1 |
| Related Headache, Dose 1 | 143 | 118 | 12 | 13 |
| Any Joint pain, Dose 1 | 137 | 87 | 14 | 13 |
| Grade 3 Joint pain, Dose 1 | 10 | 10 | 0 | 0 |
| Related Joint pain, Dose 1 | 97 | 56 | 8 | 12 |
| Any Muscle aches, Dose 1 | 266 | 193 | 26 | 18 |
| Grade 3 Muscle aches, Dose 1 | 27 | 15 | 2 | 0 |
| Related Muscle aches, Dose 1 | 194 | 131 | 16 | 17 |
| Any Shivering, Dose 1 | 70 | 44 | 5 | 4 |
| Grade 3 Shivering, Dose 1 | 8 | 5 | 0 | 0 |
| Related Shivering, Dose 1 | 42 | 30 | 4 | 3 |
| Any Fatigue, Dose 2 | 0 | 115 | 0 | 6 |
| Grade 3 Fatigue, Dose 2 | 0 | 18 | 0 | 0 |
| Related Fatigue, Dose 2 | 0 | 83 | 0 | 5 |
| Any Fever, Dose 2 | 0 | 38 | 0 | 4 |
| Grade 3 Fever, Dose 2 | 0 | 1 | 0 | 0 |
| Related Fever, Dose 2 | 0 | 23 | 0 | 2 |
| Any Gastrointestinal, Dose 2 | 0 | 55 | 0 | 3 |
| Grade 3 Gastrointestinal, Dose 2 | 0 | 6 | 0 | 1 |
| Related Gastrointestinal, Dose 2 | 0 | 29 | 0 | 1 |
| Any Headache, Dose 2 | 0 | 132 | 0 | 8 |
| Grade 3 Headache, Dose 2 | 0 | 12 | 0 | 0 |
| Related Headache, Dose 2 | 0 | 87 | 0 | 7 |
| Any Joint pain, Dose 2 | 0 | 75 | 0 | 7 |
| Grade 3 Joint pain, Dose 2 | 0 | 14 | 0 | 0 |
| Related Joint pain, Dose 2 | 0 | 52 | 0 | 7 |
| Any Muscle aches, Dose 2 | 0 | 183 | 0 | 14 |
| Grade 3 Muscle aches, Dose 2 | 0 | 21 | 0 | 0 |
| Related Muscle aches, Dose 2 | 0 | 150 | 0 | 13 |
| Any Shivering, Dose 2 | 0 | 48 | 0 | 2 |
| Grade 3 Shivering, Dose 2 | 0 | 7 | 0 | 0 |
| Related Shivering, Dose 2 | 0 | 34 | 0 | 2 |
| Any Fatigue, Across doses | 220 | 218 | 20 | 22 |
| Grade 3 Fatigue, Across doses | 22 | 30 | 0 | 1 |
| Related Fatigue, Across doses | 144 | 149 | 15 | 16 |
| Any Fever, Across doses | 54 | 80 | 4 | 7 |
| Grade 3 Fever, Across doses | 1 | 1 | 0 | 0 |
| Related Fever, Across doses | 28 | 47 | 3 | 4 |
| Any Gastrointestinal, Across doses | 121 | 132 | 18 | 13 |
| Grade 3 Gastrointestinal, Across doses | 16 | 16 | 2 | 2 |
| Related Gastrointestinal, Across doses | 68 | 73 | 12 | 7 |
| Any Headache, Across doses | 225 | 251 | 17 | 22 |
| Grade 3 Headache, Across doses | 24 | 33 | 2 | 1 |
| Related Headache, Across doses | 143 | 163 | 12 | 19 |
| Any Joint pain, Across doses | 137 | 135 | 14 | 18 |
| Grade 3 Joint pain, Across doses | 10 | 23 | 0 | 0 |
| Related Joint pain, Across doses | 97 | 89 | 8 | 17 |
| Any Muscle aches, Across doses | 266 | 287 | 26 | 26 |
| Grade 3 Muscle aches, Across doses | 27 | 34 | 2 | 0 |
| Related Muscle aches, Across doses | 194 | 224 | 16 | 25 |
| Any Shivering, Across doses | 70 | 80 | 5 | 5 |
| Grade 3 Shivering, Across doses | 8 | 10 | 0 | 0 |
| Related Shivering, Across doses | 42 | 56 | 4 | 4 |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
| Participants | Boostrix+Fluarix 19-64 YOA Group | Fluarix Boostrix 19-64 YOA Group | Boostrix+Fluarix ≥ 65 YOA Group | Fluarix Boostrix ≥ 65 YOA Group |
|---|---|---|---|---|
| Number of Subjects With Any Unsolicited Adverse Events (AEs) | 161 | 205 | 22 | 21 |
SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | Boostrix+Fluarix 19-64 YOA Group | Fluarix Boostrix 19-64 YOA Group | Boostrix+Fluarix ≥ 65 YOA Group | Fluarix Boostrix ≥ 65 YOA Group |
|---|---|---|---|---|
| Number of Subjects With Serious Adverse Events (SAEs) | 2 | 7 | 1 | 0 |
Collected over Solicited local and general symptoms: during the 15-day (Day 0-14) period following each vaccination; Unsolicited AEs: during the 31-day period (Day 0-30) following each vaccination; SAEs: throughout the whole study period (from Day 0 to Month 2).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Boostrix+Fluarix Group | 0/860 (0%) | 3/860 (0.3%) | 640/860 (74.4%) |
| Fluarix Boostrix Group | 0/858 (0%) | 7/858 (0.8%) | 619/858 (72.1%) |
| Event | Boostrix+Fluarix Group | Fluarix Boostrix Group |
|---|---|---|
| Chest painGeneral disorders | 0/860 | 2/858 |
| HeadacheNervous system disorders | 0/860 | 2/858 |
| AnaemiaBlood and lymphatic system disorders | 0/860 | 1/858 |
| Gastric ulcerGastrointestinal disorders | 0/860 | 1/858 |
| VomitingGastrointestinal disorders | 0/860 | 1/858 |
| PneumoniaInfections and infestations | 0/860 | 1/858 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 0/860 | 1/858 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/860 | 1/858 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/860 | 1/858 |
| UrosepsisInfections and infestations | 1/860 | 0/858 |
| Event | Boostrix+Fluarix Group | Fluarix Boostrix Group |
|---|---|---|
| PainGeneral disorders | 509/860 | 473/858 |
| MyalgiaMusculoskeletal and connective tissue disorders | 294/860 | 313/858 |
| HeadacheNervous system disorders | 244/860 | 276/858 |
| FatigueGeneral disorders | 240/860 | 240/858 |
| ErythemaSkin and subcutaneous tissue disorders | 203/860 | 227/858 |
| SwellingGeneral disorders | 198/860 | 177/858 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 151/860 | 156/858 |
| Gastrointestinal disorderGastrointestinal disorders | 139/860 | 145/858 |
| PyrexiaGeneral disorders | 59/860 | 88/858 |
| ChillsGeneral disorders | 76/860 | 86/858 |
| Age, Continuous(Years) | Boostrix+Fluarix Group | Fluarix Boostrix Group | Total |
|---|---|---|---|
| Mean | 48.95 ± 14.74 | 49.29 ± 14.58 | 49.12 ± 14.66 |
| Sex: Female, Male(Participants) | Boostrix+Fluarix Group | Fluarix Boostrix Group | Total |
|---|---|---|---|
| Female | 527 | 481 | 1008 |
| Male | 333 | 377 | 710 |
| Race/Ethnicity, Customized(Participants) | Boostrix+Fluarix Group | Fluarix Boostrix Group | Total |
|---|---|---|---|
| Geographic ancestry — African heritage/African American | 69 | 82 | 151 |
| Geographic ancestry — American Indian or Alaskan native | 2 | 0 | 2 |
| Geographic ancestry — Asian-Central/South Asian heritage | 0 | 1 | 1 |
| Geographic ancestry — Asian-East Asian heritage | 1 | 2 | 3 |
| Geographic ancestry — Asian-Japanese heritage | 1 | 2 | 3 |
| Geographic ancestry — Asian-South East Asian heritage | 3 | 4 | 7 |
| Geographic ancestry — Native Hawaiian or other Pacific Islander | 1 | 0 | 1 |
| Geographic ancestry — White-Arabic/North African heritage | 7 | 4 | 11 |
| Geographic ancestry — White-Caucasian/European heritage | 759 | 747 | 1506 |
| Geographic ancestry — Not specified | 17 | 16 | 33 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Ran from Oct 2006 to primary completion in Feb 2007, 4 months.
Results were first posted in Sep 2018, 11 years 6 months after primary completion.
Of 47 industry-sponsored phase 3 interventional studies under Diphtheria, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 21. This study's 4 months is below that.
Counting every sponsor, half of 47 studies reached it within 13 months; a quarter within 7 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluarix · Boostrix